Abstract
Background: Current cerebral drug delivery to the brain and Cerebrospinal Fluid (CSF) is limited by the Blood-Brain Barrier (BBB) or the blood-blood Cerebrospinal Fluid (CSF) barrier. The popular, non-invasive, intranasal delivery provides an exciting route for topical and systemic applications. For example, intranasal drug delivery of Central Nervous System (CNS) drugs can be designed to pass the BBB barrier via the nose-to-brain pathways. Recent nanotechnology research and patenting focus mainly on overcoming typical limitations including bioavailability, transport, BBB penetration, targeted delivery, controlled release rate and controlled degradation.
Objective: The aim of the present study was to assess the state-of-the-art of nose-to-brain drug delivery systems and the role of nanotechnology in targeted delivery for the treatment of CNS and related therapeutic conditions.
Methods: Patent and related searches were made with analytics to explore and organize nanotech work in intranasal drug delivery to the brain. Technical advancements were mapped by API, formulation and performance criteria. Patents and published patent applications were searched with concept tables of keywords, metadata (e.g., assignee) and patent classes (e.g., International Patent Classes and Cooperative Patent Classes).
Results: The reviewed patents and published applications show a focus on formulations and therapeutic indications related to the nano-based nose-to-brain drug delivery. The main patented materials were surface modifiers, delivery systems and excipients.
Conclusion: Surface modified nanoparticles can greatly improve drug transport and bioavailability of drugs, particularly higher molecular weight drugs. The most commonly used surface modifiers were chitosan, lectin and cyclodextrin-cross-linker complex. Nanoformulations of herbal drugs could increase drug bioavailability and reduce toxicity. Biotechnology-related drug delivery approaches such as monoclonal antibodies and genetically engineered proteins (molecular Trojan horses) deliver large molecule therapeutics.
Keywords: Nanotechnology, nose-to-brain, intranasal drug delivery, Central Nervous System (CNS), Blood-Brain Barrier (BBB), neurotherapeutics.
Graphical Abstract
Recent Patents on Nanotechnology
Title:A Patent Review on Nanotechnology-Based Nose-to-Brain Drug Delivery
Volume: 14 Issue: 3
Author(s): Ruchita Singh, Charles Brumlik*, Mandar Vaidya and Abhishek Choudhury
Affiliation:
- Nanobiz, 3322 US Hwy 22 West, Suite 421, Branchburg, NJ 08876,United States
Keywords: Nanotechnology, nose-to-brain, intranasal drug delivery, Central Nervous System (CNS), Blood-Brain Barrier (BBB), neurotherapeutics.
Abstract:
Background: Current cerebral drug delivery to the brain and Cerebrospinal Fluid (CSF) is limited by the Blood-Brain Barrier (BBB) or the blood-blood Cerebrospinal Fluid (CSF) barrier. The popular, non-invasive, intranasal delivery provides an exciting route for topical and systemic applications. For example, intranasal drug delivery of Central Nervous System (CNS) drugs can be designed to pass the BBB barrier via the nose-to-brain pathways. Recent nanotechnology research and patenting focus mainly on overcoming typical limitations including bioavailability, transport, BBB penetration, targeted delivery, controlled release rate and controlled degradation.
Objective: The aim of the present study was to assess the state-of-the-art of nose-to-brain drug delivery systems and the role of nanotechnology in targeted delivery for the treatment of CNS and related therapeutic conditions.
Methods: Patent and related searches were made with analytics to explore and organize nanotech work in intranasal drug delivery to the brain. Technical advancements were mapped by API, formulation and performance criteria. Patents and published patent applications were searched with concept tables of keywords, metadata (e.g., assignee) and patent classes (e.g., International Patent Classes and Cooperative Patent Classes).
Results: The reviewed patents and published applications show a focus on formulations and therapeutic indications related to the nano-based nose-to-brain drug delivery. The main patented materials were surface modifiers, delivery systems and excipients.
Conclusion: Surface modified nanoparticles can greatly improve drug transport and bioavailability of drugs, particularly higher molecular weight drugs. The most commonly used surface modifiers were chitosan, lectin and cyclodextrin-cross-linker complex. Nanoformulations of herbal drugs could increase drug bioavailability and reduce toxicity. Biotechnology-related drug delivery approaches such as monoclonal antibodies and genetically engineered proteins (molecular Trojan horses) deliver large molecule therapeutics.
Export Options
About this article
Cite this article as:
Singh Ruchita , Brumlik Charles *, Vaidya Mandar and Choudhury Abhishek , A Patent Review on Nanotechnology-Based Nose-to-Brain Drug Delivery, Recent Patents on Nanotechnology 2020; 14 (3) . https://dx.doi.org/10.2174/1872210514666200508121050
DOI https://dx.doi.org/10.2174/1872210514666200508121050 |
Print ISSN 1872-2105 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4020 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Current Drug Safety Recent Clinical Evidence in Bisphosphonate-related Osteomyelitis of the Jaw: Focus on Risk, Prevention and Treatment
Reviews on Recent Clinical Trials Serum MicroRNA-21 as a Biomarker for Allergic Inflammatory Disease in Children
MicroRNA Addictions and Stress: Clues for Cocaine Pharmacotherapies
Current Pharmaceutical Design Glutamate Dehydrogenase as a Promising Target for Hyperinsulinism Hyperammonemia Syndrome Therapy
Current Medicinal Chemistry Omega-3 Fatty Acids in the Management of Epilepsy
Current Topics in Medicinal Chemistry Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery Review Metabolomics: A New Approach to Drug Delivery in Perinatology
Current Medicinal Chemistry <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal EGFR(s) in Aging and Carcinogenesis of the Gastrointestinal Tract
Current Protein & Peptide Science Gene Therapy for Gastric Diseases
Current Gene Therapy Controversies About the Chromosomal Stability of Cultivated Mesenchymal Stem Cells: Their Clinical Use is it Safe?
Current Stem Cell Research & Therapy Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics
Current Medicinal Chemistry Biotherapy for Autoimmune Liver Diseases
Current Pharmaceutical Biotechnology Therapeutic Use of Heat Shock Protein 70
Recent Patents on DNA & Gene Sequences Tetralogy of Fallot and Hypoplastic Left Heart Syndrome – Complex Clinical Phenotypes Meet Complex Genetic Networks
Current Genomics CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies
Current Drug Targets Physical Enhancement of Transdermal Drug Application: Is Delivery Technology Keeping up with Pharmaceutical Development?
Current Drug Delivery Editorial [Hot Topic: Pediatricians Role in Tobacco Prevention and Control (Guest Editors: Norman Hymowitz, Dana Best and Joseph V. Schwab)]
Current Pediatric Reviews Drug Resistance in Renal Tumors of Childhood
Current Pharmaceutical Biotechnology